《半日速報》恆指升242點; 恆生科技指數升71點 港交所升逾3% 博安生物、巨子生物、中交、同仁堂國藥創新高
恆指半日收19,490點,升242點或1.3%。恆生科技指數報3,861點,升71點或1.9%。國指升103點或1.6%,報6,542點。
活躍重磅股表現:
港交所(00388.HK) 收332.6元,上升3.5%;
平安(02318.HK) 收52.05元,上升2.7%;
阿里巴巴(09988.HK) 收81.85元,上升2.3%;
建行(00939.HK) 收5.01元,上升1.8%;
友邦(01299.HK) 收79.65元,下跌1.4%;
騰訊(00700.HK) 收345.6元,上升1.2%;
美團(03690.HK) 收126.8元,上升1.1%;
異動恆指及國指成份股:
東方海外(00316.HK) 收132.8元,上升8.7%;
碧桂園服務(06098.HK) 收12.96元,上升5%;
百度集團-SW(09888.HK) 收135.3元,上升4.9%;
阿里健康(00241.HK) 收5.6元,上升4.3%;
龍湖(00960.HK) 收20.95元,上升4.2%;
京東健康(06618.HK) 收55.4元,上升3.7%;
網易(09999.HK) 收133.5元,上升3.3%;
國壽(02628.HK) 收13.04元,上升3.2%;
翰森製藥(03692.HK) 收14.2元,上升3%;
異動綜合中小型股:
博安生物(06955.HK) 收28.5元,上升46.2%,創新高;
龍光集團(03380.HK) 收0.95元,上升15.9%;
金山雲(03896.HK) 收2.55元,上升14.3%;
FIT HON TENG(06088.HK) 收1.86元,下跌11.8%;
諾輝健康(06606.HK) 收33.55元,上升10.9%;
巨子生物(02367.HK) 收54.6元,上升10.6%,創新高;
中交(01800.HK) 收4.98元,上升5.3%,創新高;
同仁堂國藥(03613.HK) 收13.36元,上升5.2%,創新高;
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.